BRPI0407487A - cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas - Google Patents

cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas

Info

Publication number
BRPI0407487A
BRPI0407487A BRPI0407487-4A BRPI0407487A BRPI0407487A BR PI0407487 A BRPI0407487 A BR PI0407487A BR PI0407487 A BRPI0407487 A BR PI0407487A BR PI0407487 A BRPI0407487 A BR PI0407487A
Authority
BR
Brazil
Prior art keywords
expression
cassette
transient
vector
exogenous molecules
Prior art date
Application number
BRPI0407487-4A
Other languages
English (en)
Portuguese (pt)
Inventor
William P Sisk
Holly Prentice
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0407487A publication Critical patent/BRPI0407487A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BRPI0407487-4A 2003-02-14 2004-02-13 cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas BRPI0407487A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (1)

Publication Number Publication Date
BRPI0407487A true BRPI0407487A (pt) 2006-02-14

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407487-4A BRPI0407487A (pt) 2003-02-14 2004-02-13 cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas

Country Status (21)

Country Link
US (2) US7494805B2 (enExample)
EP (1) EP1594955B1 (enExample)
JP (2) JP2006517802A (enExample)
KR (1) KR20050101554A (enExample)
CN (1) CN1774500B (enExample)
AT (1) ATE553185T1 (enExample)
AU (1) AU2004213797B2 (enExample)
BR (1) BRPI0407487A (enExample)
CA (1) CA2515481A1 (enExample)
DK (1) DK1594955T3 (enExample)
EA (2) EA200700469A1 (enExample)
ES (1) ES2384973T3 (enExample)
IL (1) IL170178A (enExample)
IS (1) IS7974A (enExample)
MX (1) MXPA05008523A (enExample)
NO (1) NO20054202L (enExample)
NZ (1) NZ542316A (enExample)
PL (1) PL378110A1 (enExample)
RS (1) RS20050614A (enExample)
WO (1) WO2004074439A2 (enExample)
ZA (1) ZA200506413B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700469A1 (ru) * 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
RS20060266A (sr) * 2003-10-14 2008-09-29 Biogen Idec Ma Inc., Flp posredovana rekombinacija
BRPI0508862A (pt) * 2004-03-15 2007-09-04 Biogen Idec Inc métodos e construtos para expressar multìmeros de polipeptìdios em células eucarióticas utilizando junção alternativa
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US20080166766A1 (en) * 2006-10-18 2008-07-10 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
WO2011084659A1 (en) * 2009-12-21 2011-07-14 Sanofi-Aventis Transgenic non-human animal and uses thereof
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9816102B2 (en) 2012-09-13 2017-11-14 Indiana University Research And Technology Corporation Compositions and systems for conferring disease resistance in plants and methods of use thereof
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
WO2014162318A2 (en) * 2013-03-30 2014-10-09 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
ATE229076T1 (de) 1992-04-02 2002-12-15 Sembiosys Genetics Inc Cis elemente des ölkörperproteins als regulationische signale
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1047774A1 (en) * 1998-01-16 2000-11-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ES2326893T3 (es) * 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
WO2002002765A2 (en) 2000-07-05 2002-01-10 Transgene S.A. Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び／又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
EA200700469A1 (ru) 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул

Also Published As

Publication number Publication date
PL378110A1 (pl) 2006-03-06
CN1774500B (zh) 2011-03-02
JP2010213718A (ja) 2010-09-30
WO2004074439A9 (en) 2004-12-23
AU2004213797B2 (en) 2009-09-17
US20100158879A1 (en) 2010-06-24
KR20050101554A (ko) 2005-10-24
US20060141625A1 (en) 2006-06-29
DK1594955T3 (da) 2012-06-25
RS20050614A (sr) 2007-12-31
AU2004213797A1 (en) 2004-09-02
ES2384973T3 (es) 2012-07-16
HK1084690A1 (en) 2006-08-04
IS7974A (is) 2005-08-11
IL170178A (en) 2011-12-29
MXPA05008523A (es) 2005-10-20
CN1774500A (zh) 2006-05-17
EP1594955B1 (en) 2012-04-11
US7494805B2 (en) 2009-02-24
WO2004074439A2 (en) 2004-09-02
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
EA200501296A1 (ru) 2006-04-28
WO2004074439A3 (en) 2004-10-28
ZA200506413B (en) 2006-04-26
EA200700469A1 (ru) 2008-10-30
NO20054202L (no) 2005-11-11
EP1594955A2 (en) 2005-11-16
NO20054202D0 (no) 2005-09-09
JP2006517802A (ja) 2006-08-03
EP1594955A4 (en) 2006-07-19
NZ542316A (en) 2006-04-28
ATE553185T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
BRPI0407487A (pt) cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas
BR0013248A (pt) Inibidores da adesão celular
BR0010555A (pt) Inibidores de neuraminidases
BR9806752A (pt) Ftalazinonas.
NO180538C (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer, farmasöytiske blandinger som inneholder dem og mellomprodukter ved fremstilling av derivatene
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BR0313396A (pt) 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BR9915132A (pt) Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
BR0313970A (pt) Composições pesticidas contendo ácidos dicarboxìlicos
BR9905751A (pt) Compostos de dipeptìdeo, uso e processo para preparação dos mesmos, composições fungicidas, e, processos para a preparação das mesmas, e, para combater infecções por fungos
TR200002877T2 (tr) Sülfonamid türevleri
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
BR0008689A (pt) Composição antioxidante
DK0934080T3 (da) 1,3-Bis-(N-lactamyl)propaner og deres farmaceutiske og kosmetiske anvendelse
DE60117594D1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
BR0309744A (pt) Ligandos receptores de melanocortina e composição compreendendo os mesmos
DE60027434D1 (de) Petroselinsäure enthaltendes hautpflegemittel
BR9810567A (pt) Composições antimicrobianas sinérgicas contendo uma dimetilamida de um ácido carboxìlico com uma mistura de 2-(tiocianometiltio) benzotiazol e um metileno-bis (tiocianato) e uso destes
ATE433458T1 (de) Modulatoren von ship-1
TR199800714T2 (xx) Yeni $(3-Alkoksi-fenoksi)-etil]-dialkilamin t�revleri.
DE69910019D1 (de) Verwendung von derivaten der 2-hydroxy-4-trifluormethylbenzoe säure als hemmer der aktivierung des nuklearischen transkriptionsfaktors nf-(k)b

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B25I Requirement for requested change of headquarter

Owner name: BIOGEN MA INC. (US)

B25G Requested change of headquarter approved

Owner name: BIOGEN MA INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL